vilanterol/fluticasone furoate inhaled (Rx)

Brand and Other Names:Breo Ellipta
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

vilanterol/fluticasone furoate inhaled

powder for inhalation

  • 25mcg/100mcg per actuation
  • 25mg/200mcg per actuation
  • Ellipta inhaler contains 2 double-foil blister strips, 1 containing fluticasone furoate and the other strip contains vilanterol; after the inhaler is activated, the powder within both blisters is exposed and ready for dispersion
more...

Chronic Obstructive Pulmonary Disease

Indicated for long-term, once-daily, maintenance treatment of airflow obstruction with COPD, including chronic bronchitis and/or emphysema; also approved to reduce COPD exacerbations

25 mcg/100 mcg (1 actuation) inhaled PO qDay

Asthma

Indicated for once-daily treatment of asthma for patients not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta agonist (LABA)

Use prescribe strength (25 mcg/100 mcg or 25 mcg/200 mcg per actuation) once daily via oral inhalation

Dosage Modifications

Hepatic or renal impairment: No dosage adjustment required

Geriatric patients: No dosage adjustment required

Dosing Considerations

Limitations of use: NOT indicated for the relief of acute bronchospasm

Asthma indication

  • LABAs (eg, vilanterol) increase the risk of asthma-related death
  • Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients
  • Therefore, when treating patients with asthma, physicians should only prescribe vilanterol/fluticasone furoate inhaled for patients not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA
  • Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (eg, discontinue vilanterol/fluticasone furoate inhaled) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication (eg, inhaled corticosteroid)
  • Do not use for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and vilanterol/fluticasone furoate inhaled

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Nasopharyngitis (9%)

            Upper respiratory infection (7%)

            Headache (7%)

            Oropharyngeal candidiasis (5%)

            Postmarketing reports

            Anxiety

            Tremors

            Palpitations, tachycardia

            Anaphylaxis, angioedema, rash, urticaria

            Muscle spasms

            Tremor

            Nervousness

            Paradoxical bronchospasm

            Previous
            Next:

            Warnings

            Black Box Warnings

            Long-acting beta2-adrenergic agonists (LABAs), such as vilanterol, increase the risk for asthma-related death

            A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths; this finding is considered a class effect of all LABA, including vilanterol

            Therefore, when treating patients with asthma, physicians should only prescribe vilanterol/fluticasone furoate inhaled for patients not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA

            Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (eg, discontinue vilanterol/fluticasone furoate inhaled) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication (eg, inhaled corticosteroid)

            Do not use for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids

            Contraindications

            Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required

            Hypersensitivity to drug, any components/excipients, or milk proteins

            Cautions

            LABAs (eg, vilanterol) increase the risk of asthma-related death (see Black Box Warnings)

            Increasing use of inhaled, short-acting beta2-agonists (ie, rescue inhalers) is a marker of deteriorating disease and acute episodes; reevaluate the patient immediately

            Do not initiate during rapidly deteriorating or potentially life-threatening episodes of COPD, or as rescue therapy acute bronchospasm, which should be treated with an inhaled, short-acting beta2-agonist LABAs increase asthma-related death (see Black Box Warnings)

            Do not use in combination with another medication containing a LABA because of risk for overdose

            Caution with underlying cardiovascular disease because of beta-adrenergic stimulation

            Risk of paradoxical bronchospasm, which may be life-threatening; discontinue and treat immediately with inhaled SABA

            Decreases bone mineral density following long-term administration of corticosteroids; bone fractures reported with inhaled corticosteroid use; assess upon initiation and periodically thereafter

            Corticosteroids increase risk of pneumonia; monitor for S/S of pneumonia and lung infections

            Corticosteroids increase risk of cataracts, glaucoma, and increased IOP Excessive use (or at regular dose in susceptible individuals) may result in hypercorticism and suppress HPA function; monitor closely, especially postoperatively or during periods of stress

            Corticosteroids increase risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex

            Risk for more serious or fatal course of chickenpox or measles in susceptible patients (eg, unvaccinated or immunologically unexposed individuals); care must be taken to avoid exposure to corticosteroids

            Particular care is needed to transfer patients from systemic to inhaled corticosteroids; potentially fatal adrenal insufficiency may occur before/after; taper withdrawal gradually by reducing daily prednisone dose by 2.5 mg on weekly basis

            Risk of hypokalemia and hyperglycemia

            Caution with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis

            Close monitoring for glaucoma and cataracts is warranted

            Angioedema, rash, or urticaria may occur after administration

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Unknown whether distributed in human breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Vilanterol: Long-acting selective beta2-adrenergic agonist (LABA); stimulates intracellular adenyl cyclase resulting in increased cAMP levels causing bronchial smooth muscle relaxation; also inhibits release of mediators of immediate hypersensitivity from cells, especially from mast cells

            Fluticasone furoate (FF): Long-acting inhaled trifluorinated corticosteroid with potent anti-inflammatory activity; inhibits multiple cell types (eg, mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and mediator production or secretion (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in the asthmatic response

            Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 29.9 times that of dexamethasone and 1.7 times that of fluticasone propionate

            Absorption

            Bioavailability: 27.3% (vilanterol); 15.2% (FF)

            Peak plasma time: 10 minutes (vilanterol); 0.5-1 hr (FF)

            AUC: 46% lower in patients with COPD compared with healthy individuals

            Distribution

            Following IV administration of each component

            Protein bound: 93.9% (vilanterol); 99.6% (FF)

            Vd: 165 L (vilanterol); 661 L (FF)

            Metabolism

            Vilanterol is mainly metabolized, principally via CYP3A4, to a range of metabolites with significantly reduced beta1- and beta2-agonist activity

            Fluticasone furoate is cleared from systemic circulation principally by hepatic metabolism via CYP3A4 to metabolites with significantly reduced corticosteroid activity

            Elimination

            Half-life: 21.3 hr (vilanterol); 24 hr (FF)

            Excretion

            • Pharmacokinetic studies following oral and IV administration
            • Vilanterol and metabolites: 30% feces; 70% urine
            • Fluticasone furoate and metabolites: 90-100% feces; 1-2% urine
            Previous
            Next:

            Administration

            Instructions

            After inhalation, rinse mouth with water and expectorate to help reduce risk of oropharyngeal candidiasis

            Take at same time each day

            Do not exceed 1 administration/24 hr

            More frequent administration or a greater number of inhalations (>1 inhalation daily) of the prescribed strength is not recommended as some patients are more likely to experience adverse effects with higher doses

            Patients should not use an additional long-acting beta agonist (LABA) for any reason

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous